Background Breast reduction is a generally well-tolerated procedure with high patient satisfaction and low risk of surgical site infection and other complications. While age, obesity and comorbidities have historically been used as surgical risk proxies, recent literature suggests ‘frailty’ measures, such as the modified 5-item frailty index (mFI-5), may be a superior predictor. Objectives To investigate if mFI-5 can predict the likelihood and magnitude of 30-day complications resulting from breast reductions. Methods A retrospective review was performed using the National Surgical Quality Improvement Program (NSQIP) database of patients who underwent breast reduction without other concurrent procedures, from 2013 to 2019. mFI-5 scores were calculated for each patient, and complication data were gathered. Age, BMI, number of major comorbidities, ASA class, smoking status, diabetes, steroid use and mFI-5 score were compared as predictors of all-cause 30-day complications, 30-day surgical site complications of any kind, length of stay, and aggregate Clavien-Dindo complication severity score. Univariate logistic, linear regressions and multivariate logistic regression analyses were performed to evaluate predictive value. Statistical significance was set at p < 0.05. Results A total of 14,160 patients were analyzed. The overall complication rate was 5.6%. The mFI-5 score significantly predicted overall 30-day complications, surgical site complications, complication severity, overnight stay and likelihood of readmission (all p < 0.0001). Conclusions The mFI-5 is a statistically significant predictor for adverse outcomes in breast reduction surgery. The mFI-5 is a simple and reliable tool that can be efficiently used to conduct a preoperative evaluation of patients requesting breast reductions.
Purpose To explore and report on how glaucoma care was impacted by the SARS-CoV-2 pandemic (COVID-19) in New York City (NYC) with a specific emphasis on the role of telemedicine. Patients and Methods This was a qualitative, cross-sectional study that engaged glaucoma clinicians in semi-structured interviews to elicit perspectives on telemedicine and patient care experiences during the pandemic. Interview responses were coded and analyzed thematically. Results Twenty clinicians participated. Mean participant age was 48.8 ± 12.3 years, and the mean number of years in practice post-glaucoma fellowship was 17.5 ± 12.4 years. Four main themes pertinent to the role of telemedicine triggered by the COVID-19 pandemic were identified: (1) The Need to Ensure Patient and Staff Safety Drove Telemedicine Uptake; (2) Telemedicine Allowed Providers to Address Subjective Complaints; (3) Telemedicine was Discontinued Due To Concerns of Compromised Patient Safety and Measurement Inaccuracy; (4) Technological Advances are Needed for Continued Telemedicine Usage and Uptake in Glaucoma Care. The interviews suggested that telemedicine usage dropped markedly within just a few months during the pandemic, and for most physicians interviewed, telemedicine is no longer part of their clinical practice. Several clinicians reported optimism towards future implementation of telemedicine as the technology develops. Conclusion This study identified 4 themes outlining the uptake, application, discontinuation and overall perspectives on telemedicine by glaucoma clinicians. The role of telemedicine, as triggered by the COVID-19 pandemic, may have lasting implications for patient safety, continuity of care, and glaucoma care delivery beyond this public health crisis.
Study Design: Retrospective analysis. Objective: To assess perioperative complication rates and readmission rates after ACDF in a patient population of advanced age. Summary of Background Data: Readmission rates after ACDF are important markers of surgical quality and, with recent shifts in reimbursement schedules, they are rapidly gaining weight in the determination of surgeon and hospital reimbursement. Methods: Patients 18 years of age and older who underwent elective single-level ACDF were identified in the National Readmissions Database (NRD) and stratified into 4 cohorts: 18–39 (“young”), 40–64 (“middle”), 65–74 (“senior”), and 75+ (“elderly”) years of age. For each cohort, the perioperative complications, frequency of those complications, and number of patients with at least 1 readmission within 30 and 90 days of discharge were analyzed. χ2 tests were used to calculate likelihood of complications and readmissions. Results: There were 1174 “elderly” patients in 2016, 1072 in 2017, and 1010 in 2018 who underwent ACDF. Their rate of any complication was 8.95%, 11.00%, and 13.47%, respectively (P<0.0001), with dysphagia and acute posthemorrhagic anemia being the most common across all 3 years. They experienced complications at a greater frequency than their younger counterparts (15.80%, P<0.0001; 16.98%, P<0.0001; 21.68%, P<0.0001). They also required 30-day and 90-day readmission more frequently (P<0.0001). Conclusion: It has been well-established that advanced patient age brings greater risk of perioperative complications in ACDF surgery. What remains unsettled is the characterization of this age-complication relationship within specific age cohorts and how these complications inform patient hospital course. Our study provides an updated analysis of age-specific complications and readmission rates in ACDF patients. Orthopedic surgeons may account for the rise in complication and readmission rates in this population with the corresponding reduction in length and stay and consider this relationship before discharging elderly ACDF patients.
Background: Despite established indications for orthognathic surgery, insurance coverage is not guaranteed and obtaining coverage is often onerous. There is a paucity of literature regarding insurance coverage within the United States for orthognathic surgery. Methods: The top 50 health insurers in the US, and the top 3 per state, were selected using the National Association of Insurance Commissioners (NAIC) 2020 Market Share Report. Coverage policies were obtained online, or by phone when unavailable. Indications and criteria were compared to the American Association of Oral and Maxillofacial Surgeons (AAOMF) “Criteria for Orthognathic Surgery” recommendations. Results: Of the 65 insurance providers reviewed, 33 offered coverage with clear criteria, 24 offered coverage without listed criteria, and 8 explicitly excluded all orthognathic surgery. The 33 insurers with clear criteria were further reviewed. For malocclusion, 20 insurers used at least 75% of AAOMF measurements, while 4 used stricter criteria. Eleven insurers covered surgery for any congenital disorder; of the remaining, only 13 explicitly covered cleft-associated abnormalities. For the 25 with specified speech anomaly criteria, 21 offered coverage, and 4 excluded coverage. Sleep apnea coverage criteria were inconsistent, and temporomandibular joint disorder (TJMD) coverage was evenly split. No insurer covered orthognathic surgery for esthetic or psychological reasons. Among 66 identified unique criteria, only 6 significantly differed by US Census Region, with coverage for sleep apnea more prevalent in the South District. Conclusions: Access to insurer policies remains difficult. Insurers have inconsistent covered indications, strictness of coverage criteria, and exclusions, which frequently do not match standards of care. The authors present a list of the most commonly used criteria as a resource for insurance submissions, and encourage surgeons to advocate at the insurer and legislative levels for consistent coverage indications and criteria across insurance providers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.